-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Lowers Price Target to $20

Benzinga·11/06/2026 13:07:25
Listen to the news
Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and lowers the price target from $30 to $20.